GlaxoSmithKline PLC ADR
I · AI Analysis
The brief
GSK develops and sells vaccines for diseases like RSV, shingles, flu, and HPV, plus specialty treatments for cancer, HIV, and respiratory conditions, and everyday medicines for asthma and infections [COMPANY OVERVIEW]. The company operates globally with manufacturing and research facilities, selling through hospitals, clinics, and pharmacies in over 100 countries. GSK also collaborates with partners like CureVac on mRNA vaccine technology and AN2 Therapeutics on tuberculosis therapies [COMPANY OVERVIEW].
GSK is a major UK-headquartered pharmaceutical company that makes vaccines (RSV, flu, shingles, meningitis), specialty medicines (oncology, HIV, respiratory), and general medicines (asthma, COPD, antibiotics) [COMPANY OVERVIEW]. With $32.7 billion in revenue and a 17.5% net margin, the company is financially healthy and generates $5.8 billion in free cash flow annually [Yahoo Finance]. Recent news shows Japan expanded approval for GSK's RSV vaccine Arexvy to younger at-risk adults, opening a larger market [Nasdaq].
GSK is financially strong with solid profitability, low debt, and healthy cash generation.
Sentinellis health
7.9/10
Financially healthy
Market capitalisation
$102.4B
Revenue (TTM)
GBP 32.7B
Explainers
How we read these numbers
Plain-English guides · no account needed
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
ReadPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
ReadAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
ReadII · Recent news
What moved
1 story · ranked by relevance
- Macro2026-05-18
GSK: Japan's MHLW Expands Eligible Population For Arexvy
Nasdaq
Premium · Free with any account
Dodge & Cox, the second-largest institutional holder at 2.92% of the company, cut its stake by 14.4% in the most recent quarter, a meaningful reduction that could signal concerns about near-term performance or valuation [EODHD].
Risks
4
Opportunities
4
Red flags
1
Leadership
10
8 more findings in the full report — free with any account.
Unlock the full GlaxoSmithKline PLC ADR analysis
Create a free account to access the complete AI-generated report with inline citations.
- 4 risks, 4 opportunities and 1 red flag — each with its source
- 100+ financial metrics with charts and benchmarks
- Full news summaries with source links
- Executive team and compensation details
- PDF export for offline use
III · Related
You might also read
Same sector · Healthcare — or comparable health
Want this for your watchlist?